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A B S T R A C T
Natural products have been used in the treatment of illnesses throughout the history of humankind. Exploitation
of bioactive compounds from natural sources can aid in the discovery of new drugs, provide the scaffold of new
medicines. In the face of challenging diseases, such as the COVID-19 pandemic, for which there was no effective
treatment, nature could offer insights as to novel therapeutic options for control measures. However, the envi-
ronmental impact and supply chain of bioactive production must be carefully evaluated to ensure the detrimental
effects will not outweigh the potential benefits gained. History has already proven that highly bioactive com-
pounds can be rare and not suitable for medicinal exploitation; therefore, the sustainability must be accessed
before expensive, time-demanding, and large trials can be initialized. A sustainable option to readily produce a
phytotherapy with minimal environmental stress is the use of agro-industry wastes, a by-product produced in high
quantities. In this review we evaluate the sustainability issues associated with the production of phytotherapy as a
readily available tool for pandemic control.
1. Introduction
On 11th March 2020, a huge new challenge to humankind was
established, the COVID-19 pandemic. First reported in late 2019, COVID-
19 is a viral disease caused by a novel virus of Coronaviridae family [1],
namely, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2)
[2]. Since its discovery and to date (June 2021) a staggering 175 million
people have been infected by SARS-CoV-2 and 3.7 million have lost their
lives [1]. The rate and impact of infection cannot be underestimated and
its abatement is an immediate global societal need today [3].
In record time, the scientific community was able to provide a vaccine
for COVID-19 to the population. Nearly one year was required to develop
5 different vaccines that are being applied. To date, nearly 2.2 billion
doses have already been administrated [1], yet, only 0.8% of low-income
countries population have received any dose. Low and middle-income
countries are struggling with sequential waves of COVID-19 contami-
nations due to absence of means to obtain and distribute vaccines. Such
countries are not able to produce the vaccine and are highly dependent of
commercial trade [4]. Even though those countries represents 84% of
global population, they also represent only 35% of vaccine orders [5].
Yet, in order to control a pandemic, all global population need to receive
treatment in the shorter time possible.
The challenge in providing global treatment in not merely financial,
but also involves the technological capacities of each country to manu-
facture vaccines, presence of necessary infrastructure for its storage and
distribution, and the supply chain of inputs and medicinal products [6].
The supply chain of COVID-19 vaccines is not capable to provide global
immunization on short time. In addition, medical products, such as
ventilators and sedative drugs, had their demand increased drastically
during pandemic, and their supply chain were strained, causing shortage
in many regions [7, 8, 9].
In pandemic scenarios guarantee a robust supply chain for industry
and medical treatment is essential in the process of diseases control,
economy maintenance, and society adaptation to the “new normal”.
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Sustainable technologies are one of the research lines that need to be
improved in order to achieve such goals [10]. Greenmethods not only aid
the environmental management, but also can build up local empower-
ment, reducing the dependency of low and middle income countries to
international imports and global dependent supply chains, such as those
used to provide the COVID-19 vaccine inputs [6, 10]. While global vac-
cine distribution is not possible, provide a sustainable supportive treat-
ment is mandatory to preserve life. As long as supportive treatments are
not implemented in the absence of vaccine, more are the chances for the
development of resistant strains of the virus [11, 12].
A sustainable supportive treatment that can be developed against
COVID-19 is by the use of natural bioproducts, mainly those obtained
from industrial wastes, which can provide a renewable source of mate-
rial. Natural products have been present in human history since ancient
times. There are records of their usage dating back nearly 5,000 years,
when Chinese Encyclopedias described the medicinal applications of
several plants, fungi and even animal exudations [13]. The potential of
natural bioproducts can even be observed today, for example, the
Aspirin®, acetylsalicylic acid, is a semi-synthetic derivative based on the
natural exudations from the White Willow tree (Salix alba), rich in the
glycoside salicin that is easily metabolized into salicylic acid [14]. In
addition, half of the habitable area on Earth is used by agriculture, within
which approximately 23% is designated to crops with a total production
larger than 1 billion tons per year [15]. Of the massive production of
crops, nearly half of them become waste. Agro-industrial wastes are
extremely difficult to be properly disposed and are usually not properly
treated, causing severe damage to the environment and animal health
[16, 17, 18].
The exploitation of natural products to develop supportive treatments
had already proved its feasibility during human history [19]. Yet, it has
been poorly explored in the combat to COVID-19 pandemic [20, 21],
even though the World Health Organization recognizes the existence and
importance of phytotherapy, particularly in low-income countries [22].
Does natural based treatment be a reliable and sustainable tool in middle
of the chaotic scenario of COVID-19 pandemic? In this review we aim to
provide an insight into the value of natural products in COVID-19
treatment and the sustainability issues of exploiting these natural
products.
2. The COVID-19 case
The COVID-19 pandemic has become a seriously health public issue,
even though its estimated mortality rate is lower than others coronavirus
which were also pandemic in the past (SARS and MERS) [23]. One of the
issues is the vulnerability of people which has comorbidities such as
diabetes, hypertension, and many other cardiovascular diseases [24],
that currently have a high occurrence rate globally [25]. The suscepti-
bility of non-communicable comorbidities patients to get severe forms of
COVID-19 is related to the inoculation and replication system of the
virus. The mechanism of SARS-CoV-2 infection and replication (Figure 1)
is via the expression downregulation of the angiotensin converting
enzyme type II (ACE2). Because of this interaction SARS-CoV-2 affects
the homeostasis of the cardiovascular, diabetic and respiratory processes.
Once the virus interacts with ACE2 through the 3 chymotrypsin-like
proteases (3CLpro) present on its surface, the virus enters the host cell,
which is promoted by protein cleavage of the transmembrane protease
serine type 2 (TMPRSS2). At this point on, SARS CoV-2 RNA is released
inside the cell and the virus starts to replicate [20].
COVID-19 generates several problems to society not only related to
mortality. Psychological diseases had exponentially increased,
manpower in several production lines had drastically decreased, global
economy was severely affected, supply chains in diverse industrial lines
collapsed with the increasing demands. The world is not the same as
before November, 2019. There are several ways to treat viral diseases,
such as drug repurposing, supportive drug development, and vaccine
development. Drug repurposing was the first strategy used against
COVID-19 since the development processes for a new drug or vaccine
usually take several years, if not decades. It is a common alternate,
particularly as a strategy for pandemic disease control [26]. However, in
the case of COVID-19, the rapid drug repurposing of traditional
anti-malarials (chloroquine and hydroxychloroquine) backfired as they
show little or no efficacy against SARS-CoV-2 [27]. In the case of
Figure 1. SARS-CoV-2 main inoculation mechanism.
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hydroxychloroquine, the use of these drugs even increased the incidences
of heart attack. Currently, the repurposed drugs have questionable effi-
cacy in the treatment of COVID-19 [28].
The time record develop of vaccines was a flash of hope in pandemic
ending, yet, none of them are fully optimized. Vaccines are considered
well-consolidated and fully optimized, such as those for HPV and hepa-
titis B (Table 1), if they have high efficacy, can be easily transported to
any place, require only standard freezing, and do not degrade easily
under storage. On the contrary, the Ebola vaccine has not been fully
optimized as its storage and transportation logistics make it inaccessible
in a global perspective [29, 30, 31]. The Ebola vaccine requires a storage
temperature at -60 C and its distribution in times of emergency is
extremely complicated in countries that do not have a stablished
ultra-cold chain for products distribution. For instance, during the
STRIVE test, performed in Sierra Leone, West Africa, the urgent imple-
mentation of an ultra-cold chain for distribution of Ebola vaccine was
evaluated. The implementation cost was significantly high for the
country. Critical issues highlighted in STRIVE test were that ultra-cold
chain requires overly expensive infrastructure, electricity supply, and
specialized human resource to track and monitor the vaccine throughout
the chain [32]. The results of STRIVE test elucidates that less than 30
countries have the structure to quickly implement ultra-cold chain for the
distribution of vaccines that requires such low temperatures [32, 33].
This is one of the many reasons that underdeveloped countries are
struggling with their vaccination campaigns [32].
Even though the scientific community has managed to develop a
vaccine in a record time, there is still much uncertainty. There is no
precise information about how long the vaccine will be effective, part of
the global population is afraid to be vaccinated, middle and low-income
countries cannot afford massive vaccine programs and are depending on
other countries for vaccine production. While a few countries are
vaccinating their population rapidly and on schedule, too many others
are unable to follow the same immunization rhythm, and still have
increasing infection rates, which are creating more resistant variants of
the SARS-CoV-2 virus [34]. In face of such challenges imposed by
COVID-19, every available possibility to aid pandemic restrain must be
explored. Sustainable options for supportive treatments can be the hope
until the vaccines are fully optimized or equally available worldwide.
3. Natural metabolites and the SARS-CoV-2
Throughout human history viral diseases have been notoriously
difficult to fight as they incorporate themselves into a host system and
can quickly mutate to become resistant to drugs or vaccines. For instance,
there is no effective prophylactic or cure for the SARS-CoV (recognized in
2002) and HIV (recognized in 1981) until today [27, 35], highlight the
complexity involved in creating safe treatments and vaccines for viral
diseases.
Several viral infections are treated after infection through symptom
management or inhibit virus replication [36]. These strategies are also
known as supportive treatments. The aim of these strategies is to prevent
disease development by treating the infection in its early stages. The
supportive treatment can be done by neither synthetic and semi-synthetic
drugs, and phytomedicine [27]. In general, phytotherapies are associated
with less side-effects to the patient and have higher acceptance by ci-
vilians as a alternative for primary health care [37]. Plants undisputedly
play a major role as sources of medicinal substances, though many other
organisms have been used, such as marine organisms [38], microor-
ganisms [39], endophytic fungi [40], higher plants [19], and metaboli-
cally engineered organisms [41, 42].
Currently, several existing, catalogued, natural products are being
tested via in silico assays as potential anti-COVID-19 drugs [20, 43]. In
silico trials are a fundamental step in the prospection of bioactive com-
pounds, as these computational simulations lessen the need for
time-consuming laboratorial procedures. The goal of these tests is to
predict which metabolites may interact with the enzyme and protein
involved in the SARS-CoV-2 inoculation mechanism, with the viral RNA
directly (Figure 1), or treat the infection symptoms (e.g. inflammation of
upper respiratory tract and obstructive pulmonary disease) [44].
Some of the best in silico results for anti-SARS-CoV-2 involve glyco-
sylated flavonols, flavanones, terpenoids, and alkaloids, such as naringin,
naringenin [45], baicalin, hesperitin [46], eugenol, pseudojervine [20],
6-gingerol, quercetin [45], and myricetin (Figure 2) [47]. These com-
pounds have better inhibition, in silico, than most repurposed drug can-
didates. Briefly, their main active site against SARS-CoV-2 is through
inhibition of ACE2 and TMPRSS. Chemical classes, such as terpenoids,
have lower binding energy with 3CLpro, reducing virus ability to bind in
cellular membranes acting directly in the virus structure [48, 49]. In
addition, terpenic acids, such as oleanolic acid, also show promising re-
sults as RNA polymerase inhibitors of SARS-CoV-2. The RNA polymerase
inhibition is a particularly interesting mechanism in drug development
due to its specificity to the virus as opposed to host proteins (ACE2 and
TMPRSS2) [50].
The search for natural products that are bioactive against SARS-CoV-2
is mainly in the in silico phase, and the most prominent results are focused
on isolated compounds, without proper analysis of their sustainability for
such application [20]. Closer evaluation of natural metabolites with
suggested anti-COVID-19 activity identifies several other problems
associated with the usage of isolated compounds. For instance, pseudo-
jervine has a low lethal concentration for humans [51]; gingerol pro-
motes a burning sensation [52]; baicalein and baicalin are products of a
very specific specialization of the cinnamic acid pathway, being
extremely difficult to obtain from plants [53].
On the other hand, part of the specialized metabolites with prom-
ising in silico results have a more consolidate data regarding their me-
dicinal application and are more easily obtained from natural and
synthetic sources. Examples of it are methyl eugenol, oleanolic acid,
and ursolic acid which are widely distributed within plant species. It is
estimated that these metabolites have already been identified in at least
300 (methyl eugenol) [54] or 1500 (oleanolic and ursolic acid) [55]
distinct species of several botanic families. Most of these botanic spe-
cies are inserted in the human diet, as fruits or vegetables, or used as
medicinal herbs. Examples of natural sources containing these metab-
olites include Beta vulgaris L., Oleandra neriifolia L., Ilex paraguariensis
St. hil., Glechoma hederacea L., Crataegus pinnatifida Bge., Vaccinium spp.
(blueberry), Olea europaea L. (olive), and apple peels [56]. The broad
Table 1. Vaccines features related to sustainability.
Vaccine or Developer representant Long term storage duration Short term storage duration Efficacy Ref.
HPV 3 years/2–25 C 1 year/ 37 C Close to 100% [27]
Hepatitis B 3 years/2–8 C 1 month/ 37 C 80–100% [27]
Ebola rSVΔG-ZEBON-GP -60 C 12 hours/2–8 C 97–100% [26, 28]
Oxford/Astrazeneca -4 C - 62–90% [29]
Moderna 6 months/-20 C 30 days/2–8 C 94% [30]
Pfizer/BioNTech -70 C 5 days/2–8 C 95% [31]
Sputnik V -4 C - 91.4% [32]
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distribution of methyl eugenol, oleanolic and ursolic acid in several
botanic species makes them great promising lead-compounds. It is
worth mentioning that methyl eugenol preliminary in silico studies
evidence methyl eugenol binding energy with SARS-CoV-2 spike pro-
tein at -8.29 kcal mol1 [57], a result similar to the repurposed drugs
[58]. The botanic families with major occurrence of those triterpenoids
(ursolic and oleanolic acids) include Asteraceae, Apiaceae, and Lam-
iaceae. Depending on the species and cultivars, the concentration of
these compounds can be as high as 100 mg per 100 g of fresh raw
material (fruits or leaves) [59, 60]. In addition to their recent sugges-
tion as possible anti-SARS-CoV-2 metabolites [48, 57], methyl eugenol,
oleanolic acid and ursolic acid were already known for possessing
several biological activities, such as anti-inflammatory, antioxidant,
anti-leishmaniasis, antibacterial, neuroprotective, and antiviral. For
instance, ursolic acid has bioactivity against hepatitis B and C and
influenza viruses [61], while oleanolic acid has anti-HIV activity and
was used as a scaffold for anti-HIV drugs [55].
Another interesting chemical classes already tested in silico is the
flavonoids, which natural abundance can become useful in the supply
chain for a phytomedicine against COVID-19. The flavonoids naringin,
naringenin, hesperetin, and hesperidin binding energy with SARS-CoV-2
proteins ranged from 6.09 to 7.0 [20], also results close to suggested
repurposed drugs, such as Hydroxychloroquine and Azithromycin [58].
These compounds are the major flavonoids within several Citrus genus
(Rutaceae) species. In fact, their premature identification as possible
phototherapeutics against COVID-19 was because they are common in
Chinese medicinal herbs, and therefore are catalogued in their databases
[62].
Figure 2. Natural metabolites within in silico results against SARS-CoV-2.
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In addition to controlling SARS-CoV-2 replication in the organism,
natural metabolites can also be used to control other clinical manifesta-
tions caused by the virus. During COVID-19 infection, of moderate and
severe presentation, patients experience several clinical conditions that
deteriorate health and recovery chances. SARS-CoV-2 clinical manifes-
tations include neuroinvasion, neurotropism, cellular death, inflamma-
tory process of tissue, pneumonia, reduction of lung capacity, lung
obstruction, arrhythmia, kidney failure, and arthralgia [1]. For such
clinical conditions, several natural products are already known. Phyto-
therapy bioproducts have been used in the treatment of viral infections,
as they are able to control clinical manifestations induced by virus and
their viral load in the organism [63]. For instance, phytotherapy derived
from honey (Echinacea species) are recognized as anti-inflammatory,
cardio protectors, and antivirals against influenza, HIV, herpes and
rubella [64]. As Echinaceametabolites are serine protease inhibitors, they
can be used in the treatment of the beforementioned clinical conditions
of SARS-CoV-2. [44].
China is one of the major countries which applies phytotherapy in
disease treatment. In this country, which is the epicenter of the SARS-
CoV-2 pandemic, medicinal herbs were adopted as supportive treat-
ment to COVID-19, depending on the clinical stage. In Chinese medicine,
COVID-19 was treated as a viral influenza-like disorder. The clinical
stages are divided into four: Prevention (healthy or asymptomatic pa-
tients); early (mild symptoms, such as fever, sore throat, shortness of
breath, intestinal disorders); late (pneumonia, obstructing the lung); and
recovery (sequelae of diseases, such as deficiency of the lung) [65]. Small
clinical trials were developed in Wuhan, northeast Chongqing, and
Taiwan, using a mixture of Chinese herbs, which included Scutellariae
species [66, 67, 68]. In all cases, the phytotherapy were used in the late
stage of the disease, to treat pneumonia and lung obstruction. Improve-
ment of clinical conditions were monitored with chest tomography and
COVID-19 RT-PCR test. Despite the small size of patients evaluated, all
researchers reported that the application of Chinese traditional herbs
alleviated lung obstruction and reduce the hospitalization period [66, 67,
68].
The chemical composition of the traditional Chinese Herbs prepara-
tion adopted in such treatments was investigated by Tsai et al. (2021)
[66] and Lee et al. (2021) [69]. The major basis of Chinese phytomedi-
cine against COVID-19 was based in the Glycyrrhiza species and Scutel-
laria baicalensis. The Glycyrrihyza extracts (licorice) and its major
metabolite glycyrrhizin are recognized medicinal bioproduct with large
economomic importance to pharmaceutical and cosmetic industries.
Currently, both bioproducts are already in vitro test against COVID-19,
with a suggested dose for clinical randomized trials varing from 10 to
50 mg of glycyrrhizin [70]. In the Scutellaria baicalensis, the major
bioactive compound identified was baicalin, with a concentration of 2.38
mg mL1. In addition, other compounds, such as caffeoylquinic acids,
glycosylated flavonoids, flavanones, and flavones were also detected
[66]. Baicalin-rich extracts tested in vitro against COVID-19 also had
proeminet results with a EC50 of 10.27 μM, nearly 10 times higher than
hydroxychloroquine [20].
Those traditional Chinese herbal preparations were also demon-
strated to have multiple mechanisms in the treatment of COVID-19
symptoms and sequela, acting as an antiviral and anti-inflammatory.
Although the precise mechanism is uncertain, the chemical profile of
the herb indicates that it possible that it acts in different sites to inhibit
SARS-CoV-2 proliferation [68, 69].
The results of this phytotherapy alternative tested in China
for COVID-19 were preliminary, however, it was only possible because
of the remarkable presence of the Traditional Chinese Medicine in
the health system. Clinical conditions such as flu and other viral dis-
eases are commonly treated with supportive phytotherapy [65]. In
other words, medicinal herb preparations are already available in the
health system. However, a phytotherapy option must have a sustain-
able characteristic that enable efficacy tests, clinical trials, and
production.
4. Natural products perspectives against COVID-19 pandemic
Discovery of bioactive natural products and their application in dis-
ease treatment requires as much care as that of any other synthetic drug.
In a pandemic scenario, in which time is crucial to preserve life, several of
these questions are related to cost-benefit and risk-benefit. For instance,
in the case of chloroquine and hydroxychloroquine, the cost-benefit was
accessible, as it was a drug that is well-consolidated in the market.
However, the risk-benefit was not accurately measured. The consequence
was a great insecurity in whether those drugs are safe or not. After
widespread use by society, research have come forth reporting the car-
diovascular dangers of those drugs and their little to no efficacy against
COVID-19 [71, 72].
For a bioproduct to be sustainable in a pandemic scenario, several
aspects must be carefully considered (Figure 3), that includes general and
specific features of drug and phytotherapy development [73]. Atten-
dance with such aspects can provide treatments capable of being deliv-
ered efficiently worldwide thus restraining the pandemic scenario. These
aspects briefly involve supply chain, safety, and optimization for
worldwide commercialization.
A major concern in pandemic control is that the treatment has to be
available as fast as possible to all society. The high financial cost of
vaccines is one of the drawbacks in the global control of COVID-19 [4].
The supply chain regards not only the final availability of the product,
but also the availability of any material necessary to manufacture it. In
developing bioproducts, the initial concern in the supply chain is the
availability of the bioactive compound or bioactive extract and its raw
source.
For medicinal purposes, several in vitro, in vivo, pre-clinical, and
clinical assays must be performed with the drug of interest. Thus, even
before pre-clinical testing, a significant amount of the medicine must be
available for test. For instance, in pre-clinical trials of a phytotherapy it is
recommended that nearly 50 kg of the raw material be available [74].
Raw material in phytotherapy can be any vegetative or reproductive
organ, and even byproducts, such as oleoresins and essential oils. In
natural conditions, obtaining that amount of raw material can be
extremely challenging. For example, the Copaifera genus oleoresin is a
worldwide popular phytotherapy, however, each Copaifera tree can
present a very distinct quantity of oleoresin. It is estimated that,
depending on the species and geographical region, the yield of oleoresin
can vary from 0.1 to 60 L per tree, with sampling intervals of at least three
months [75, 76]. In addition, approximately only 25% of Copaifera trees
produce oleoresin and their spatial distribution in native forests is close
to 1.7 trees per hectare [76, 77]. Obtaining Copaifera oleoresin becomes
even harder as the extraction procedure requires digging a hole in the
trunk, which can result in tree death [76].
The Copaifera example highlights how difficult it can be to obtain raw
natural product material in natural conditions. The same problem can be
observed in several herbs from the Chinese Traditional Medicine. The
Scutellaria baicalensis is a species endemic in China, with lower occur-
rence in Japan, Korea, and Southeast Asia. Regardless of its inclusion in
the Chinese Pharmacopoeia and extensive clinical usage in China, species
domestication was not incentivized until approximately 2010, the
moment in which wild populations started to significantly decrease [78,
79]. The increasing cultivation by small farmers with no proper domes-
tication study also introduced poor quality S. baicalensis, with less than
90 mg of baicalin per gram of root, into the market [78].
Those issues with S. baicalensis cultivation indicates that the herb
would not be sustainable in a scale larger than its current demand, which
could present problems in attending pre-clinical and clinical tests of ef-
ficacy against COVID-19. Exponential exploitation of S. baicalensis could
cause a severe environmental impact, with wild populations decreasing
uncontrollably, or safety problems if the reproducibility of S. baicalensis
extract quality cannot be ensured. Note that indications of S. baicalensis in
the treatment of COVID-19 applied the plant extract [69]. Despite bai-
calin and baicalein can be present in high quantities in plant extracts (36
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mg–90 mg per gram of root), it can only be obtained in few species of
Scutellaria genus [80, 81]. Thus, application of baicalein and baicalin in
anti-COVID-19 phytomedicine development would have to rely on
semi-synthetic or synthetic production. As these compounds were
already known there are already options for synthetic routes and cell
cultures, with relatively low cost and high yield for commercialization
[53, 80, 82].
Basically, the same issues are observed with the Glycyrrhiza species.
As an endemic species in China, their density worldwide is low and the
wild populations are threatened since 2010 due to their exploitation
[83]. The bright side is that as a phytomedicine already exploited by
humankind, there is already safety studies regarding their consumption
by humans [84]. As glycyrrhizin and licorice extracts are mainly obtain
from the root of few Glycyrrhiza species, its sustainable application dur-
ing pandemic in larger communities would requires synthetic and
semi-synthetic production routes as well.
Despite the outstanding potential and applicability of natural prod-
ucts in the development of medicine, an recurrent issue is their avail-
ability and environmental impact [85]. As important as developing a new
treatment for COVID-19 with licorice or S. baicalensis, their efficacy
against pandemic will be based in their supply chain. Even if they have
formidable benefits to the treatment, if they cannot be supplied in suf-
ficient content, it will be of little help, as many other natural products
before. An example of this issue is the Paclitaxel®. Paclitaxel is an iconic
case of a highly bioactive natural product with several drug development
sustainability issues [86]. Taxol is a remarkable natural anti-neoplastic
compound, firstly obtained in the bark of Taxus brevifolia. However, its
concentration in the bark was only 0.05% and after few decades of
exploitation, the species was nearly extinct [86]. In addition, Taxol is a
very complex substance, with 11 asymmetric centers, not produced by
any other plant species. Its total synthesis, microbial production, or in cell
cultures showed no economic feasibility [86, 87]. It took several decades
to find an alternative source from another plant species (Taxus baccata)
where a similar substance would be extracted from the leaves and be able
to be converted to Taxol in only some economically viable chemical
synthetic steps [88]. Nevertheless, the pharmaceutical formulation of
such a nonpolar compound was only achieved by several of the most
aggressive collateral effects until recent advances in nano-formulations
[86, 87].
5. Challenges and opportunities
Consolidate a natural product in pharmaceutical industry from its
natural source have always being a challenging task. Even today, there
are fewmedicinal drugs of such type commercialized by large companies.
Most of them are local phytomedicine from small to medium size pro-
ducers [88]. The great challenge in this task, as previously illustrated is to
obtain a robust source of the raw material, without causing environ-
mental impact, and with homogeneous characteristics (e.g. chemical
composition, which in plants is extremely variable by biotic and abiotic
stress) [85, 88].
Produce a pharmaceutical drug from natural source are difficult as
taxonomy identification of plant in wild is tough. Several methods such
as morphological, microscopical and DNA analysis need to be performed
to ensure the identity of the tree. If a different species is used it is possible
to not achieve the desire effect, or even intoxicate the patient. In many
cases, the species will be of difficult access, or not domesticated. And
even if there a dense population of the species, plants chemical compo-
sition changes during their life cycles and different seasons [85]. An
strategy to ensure a robust supply chain with more homogeneous
composition through time is to rely on already domesticated crops or
even on the agro-industrial wastes.
Considering the robustness of a supply chain, licorice and
S. baicalensis are not suitable to be used during pandemic as a natural
source. Both bioproducts are mainly undomesticated, with a dense
population centered on China. For instance, licorice roots global
Figure 3. Sustainability features for bioactive production.
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productions was 40,911 tons in 2004 [89], a yield easily surpassed by
domesticated crops, such as ginger roots (production of 1,256,777 tons in
2004) [90].
Previously we seen that compounds such flavonoids and terpenoids
had promising results in preliminary test against COVID-19 [20]. What if
there is a robust and homogenous source of them? Compounds such as
baicalin, baicalein, naringenin, naringin, eugenol and methyl eugenol
can be found in several other higher plants [86, 91]. In addition, these
compounds were also reported to be present in agro-industrial waste of
Citrus [92, 93] and apple pomace [94, 95].
The major advance of agro-industrial waste as raw material in treat-
ment development is that they are constantly produced. In addition, their
management also follows a sustainable perspective as less residues will
be discharged in nature [85, 96]. For instance, in 2019, the production of
apples was 87,236,221 tons and oranges reached 78,699,604 tons.
Considering the residue-to-product rate for apple pomace is 0.25 and for
orange pomace is 0.37, the residues of just these two fruits reaches more
than half a billion tons in a single year (apple¼ 348,944,844 tons; orange
¼ 212,701,632 tons) [90]. Use of this huge amount of raw material for
extracting natural bioactive products could bypass most of the sustain-
ability issues already described. Thus, even in face of the supply chain
crisis caused by COVID-19 pandemic, those raw materials can be of
interesting for treatment development.
5.1. Citrus
As one of the major commercialized natural products, Citrus already
have a well-established production chain. Several studies have evaluated
the reuse of its industrial waste, although its waste usage to promote
value-added products is still not as consolidated as the production of
industrialized products, such as juices or frozen pulps [97, 98]. Citrus
waste valorization has many branches, such as the extraction of phenolic
compounds and flavonoids, carotenoids, pectin, limonoids, and even
essential oils [99, 100]. Depending on the waste characteristics and the
bioproduct wanted, there are plenty extraction options applicable to
large-scale industries and different types of biorefineries [101]. Citrus
agro-industrial waste management has been encouraged since the waste
can cause several environmental problems, such as the severe reduction
in soil fertility due the presence of alkalis, antimicrobial compounds, and
organic matter with low nitrogen content (which difficult microbial
decomposition) [102]. The administration of Citrus wastes is such an
important issue that as juice commercialization increases, several re-
searches have been performed to develop methods to afford the creation
of value-added products [98, 103].
Within the four flavanones with high in silico docking with SARS-CoV-
2, naringin and hesperidin, are the most concentrated in Citrus, especially
in its peels and pericarp. For instance, Citrus reticulata (Chinese mandarin
orange) has one of the highest concentrations of both flavanones
(Table 2). Citrus peel corresponds to nearly 40–65 % of its weight with
respect to the whole fruit and is a major unavoidable food supply chain
waste. An estimated 40 million tons of residue per year are produced
[101]. As Citrus flavanones appear to have anti-SARS-CoV-2 activity [46,
104], the Citrus peel waste can become a reliable source of such metab-
olites for the development of anti-COVID-19 bioproducts. For instance, a
country such as Brazil, which is struggling with consecutives waves of
infection [105], and is the largest producer of oranges and its byproducts,
Citrus waste potential as anti-COVID-19 treatment can be a light of hope.
Flavonoid extraction from Citrus peel wastes can be accomplished by
several methods, which varies from simple percolation with water to
more refined methods, such as ultrasound assisted extraction (UAE)
(Figure 4). Some issues to be considered in the extraction of anti-SARS-
CoV-2 flavanones of Citrus peels include time, cost, toxicity, and purity
obtained through the process [46]. Most applied methods include
acid-base and Soxhlet based extraction. Despite their robust usage,
extraction with those methods would not be recommended for such a
hurry urgent pharmaceutical application, as they include the usage of
large amounts of highly toxic solvents [101, 106]. These characteristics
increase the presence of solvent residues in the final product.
Other options of extractive procedures include percolation with
hydroalcoholic solvent (50%–70% water content) [107]. In this case, the
usage of methanol and ethanol produce similar extraction yields of Citrus
flavanones. Taking into account the toxicity, ethanol is a good option for
pharmaceutical approaches [108]. Usage of pure water as a solvent had
also recently been presented as a viable option in a pilot scale study,
though by hydrodistillation or even UAE [101, 107]. Despite the lower
implementation cost of hydrodistillation and percolation, both methods
usually require heating, which must be carefully controlled as flavonoids
can undergo thermal degradation [46, 108]. It is worth mentioning that
sustainable biorefineries with low energy consumption could be imple-
mented in the case of hydrodistillation to enhance the total concentration
of Citrus flavanones in extractions [108].
Ultrasound assisted extraction (UAE), hydrodynamic cavitation (HC),
and microwave assisted extraction (MAE) enable efficient flavonoid
extraction without the use of high temperatures, such as those commonly
applied in hydrodistillation methods, thereby avoiding thermal degra-
dation issues [107]. Within those methods, MAE presents the highest
implementation difficulties for operational industries, as its equipment
has lower capacity and higher associated cost when compared to the
others [107, 109].
As a highly chemo diverse matrix, pre-treatment methods for Citrus
waste management had been developed and are recommended for the
extraction of specific phytochemicals. Among them, biocatalysis with
microorganisms demonstrated reliability in obtaining higher concentra-
tions of hesperitin and naringenin rather than glycosylated derivates
[110, 111]. Thus, even after in vitro confirmation of the bioactivity of
each flavanone form against COVID-19, it would be possible to
Table 2. Concentration (mg.g1) of major anti-SARS-CoV-2 flavonoids in dried citrus peels.
Species Naringin Naringenin Hesperidin Ref.
Citrus reticulata "Chaci" 3.409 n.i 62.919 [84]
Citrus reticulata "Erythosa" 0.556 n.i 74.236 [84]
Citrus reticulata "Subcompressa" 0.582 n.i 100.525 [84]
Citrus reticulata Blanco 0.79 2.07 39.39 [83]
Citrus reticulata Blanco var. porcan 1.37 0.86 3.49 [83]
Citrus reticulata 0 0 0.026 [85]
Citrus aurantifolia 0.8 0.85 28.3 [83]
Citrus aurantium x reticulata var. murcote 0.96 1.8 2.27 [83]
Citrus limettioides 0.88 0.47 2.1 [83]
Citrus sinensis L. Osbeck 0 0 8.61 [83]
Citrus sinensis L. Osbeck var. baía 2.06 1.78 41.17 [83]
Citrus clementine of Citrus reticulata (clementine) 0 0.007 33.13 [85]
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specifically obtain any of them from Citrus peel waste with no greater
addition of technology to the biorefineries.
5.2. Apple pomace
Apple pomace is the name given to the industrial residue of apple.
This material is composed of peels, seeds, and pulp, usually from the
species Malus  domestica Borkh. As a well domesticated and cultivated
species around the world, each region will have an apple pomace of a
specific variety and with distinct proportions of its fruit parts [112].
Apple pomace has been exploited in the last decades as a rich source of
phytochemicals and vitamins. In fact, part of its commercial exploitation
is in regards to the extraction of ursolic acid, to create high-value added
bioproducts [94, 113].
This industrial residue has a highly chemo diverse composition,
mainly with carbohydrates, fatty acids, and phenolic compounds. The
most valorized metabolites obtained from apple pomace include pectin,
chlorogenic acid, ursolic acid, and glycosylated flavanones, flavanone,
flavones, and flavanols. Interestingly, the major occurrence of flavanones
in apple pomace are as naringenin and hesperetin [103], as previously
mentioned, compounds with great potential as anti-COVID-19 metabo-
lites. With the large concentrations of naringenin (up to 75.6 mg kg1 of
dry weight), hesperetin (up to 676 mg kg1 of dry weight) [103], and
ursolic acid (average of 400 μg g1 of fresh weight) [94] in apple pomace,
this residue can be a reliable source, not only to isolate those compounds,
but also to create bioactive extracts.
Issues concerning the application of apple pomace in COVID-19
treatment development the extraction, isolation, and purification pro-
cess. The standard method used to isolate ursolic acid from apple pomace
includes a pre-treatment with decoction, Soxhlet extraction with
increasing polarity solvents, recrystallization and purification on a
chromatographic column (Figure 5) [94]. The Soxhlet extraction has a
yield of ursolic acid of 3.5% with a purity of nearly 60% [94]. Similar
results can be achieved with the use of UAE (yield of 2.9% and purity up
to 97%), which can reduce organic solvent residues in the final product,
as the developed method uses only methanol [113]. Another advantage
of the non-convection extraction method is related to energy consump-
tion and safety, as Soxhlet requires boiling organic solvents. The major
issue in the ursolic acid extraction from this matrix is the presence of
carbohydrates, which interferes in the purification process. In any case,
pre-treatment of the matrix to remove carbohydrates is a fundamental
step in order to obtain a high value-added product and increase process
efficiency [94, 112].
6. Concluding remarks
The development of therapeutic strategies is a greater task than just
finding a bioactive compound. It becomes even more critical if the new
medicines must be readily available on a global scale. Even thought
several vaccines against SARS-CoV-2 are already available, supportive
treatments are still needed and urgent to control pandemic, as many
countries are struggling to acquire any vaccine. As phytomedicine is
more accepted by society than synthetic drug, now more than ever after
hydroxychloroquine mistakes, natural products are being investigated as
tools to develop new treatments more often. Preclinical trials have sug-
gested that Traditional Chinese Medicinal Herbs, Scutellaria baicalensis
and licorice roots can be promising in the treatment of COVID-19 pa-
tients. However, such herbs have a major supply issue, both of them are
Figure 4. Major extraction methods of Citrus peels waste flavanones.
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mainly cultivated in small scale and are not fully domesticated. Providing
high quantities of natural product for quick response in a pandemic
scenario requires a consistent supply source.
The in silico and in vitro tests also suggests that common occurrence
natural metabolites, from flavonoids and terpenoids chemical classes,
can be promising active compounds in a supportive treatment of COVID-
19. The greater advance of such compounds is that they can be found in
several plants, including domesticated species.
In this scenario, two natural products have drawn attention: the Citrus
peel wastes and apple pomace. These bioproducts are rich source of
suggested anti-COVID-19 natural metabolites. As they are agro-industrial
waste of massive production worldwide, the supply chain is more robust
than the ones of Scutellaria and licorice extracts. The domestication and
high production make agro-industrial waste more sustainable than in
natura bioactive, particularly for the immediate response required for
diseases such as COVID-19.
Treatment development for such challenging diseases must be fast.
Yet, the only concern cannot be in how fast we can obtain an anti-COVID-
19 treatment but also the efficacy and sustainability of the newmedicine.
All development phases must be carefully accomplished and data must be
analyzed thoroughly. Science must, and can, solve the problem, while
avoiding creating new ones, such as in the case of Taxol. After ensuring
initial risk of supply and efficacy, other questions must be addressed,
such as production standardization, bioavailability, side-effects, and
phytotherapy-synthetic drugs interaction. Using the best of our knowl-
edge on chemical composition of biomass waste materials to take full
advantage of natural resources seems to be the proper and sustainable
way to increase development with conservation.
Figure 5. Ursolic acid extraction methods.
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